Literature DB >> 11486342

Transplantation and gene therapy: combined approaches for repair of spinal cord injury.

M Murray1, I Fischer.   

Abstract

Motor and sensory functions are lost after spinal cord injury because neurons die or atrophy and axons fail to regenerate. Until fairly recently, it was believed that damaged neurons could not be replaced and injured axons could not regenerate, and, therefore, functions dependent on injured neurons could not be recovered. We now know that damaged neurons can be rescued by providing therapeutic factors or replaced by grafting. In addition, the adult CNS contains a population of precursor cells with a potential to generate new neural cells, whose numbers and composition can be modified by extrinsic factors. The pioneering studies of Aguayo demonstrated that CNS axons could regenerate in the right environment. Subsequent studies have revealed the identity of some of the inhibitory molecules in myelin and scar tissue, and we now have a better understanding of how the CNS environment can be modified to become more permissive to regeneration. Axons that regenerate must find an appropriate target, but it may not be essential to reestablish the precise topography for some functions to be restored. There are now new and promising strategies for delivery of therapeutic genes to protect neurons and to stimulate regeneration. The ability to engineer cells by gene therapy combines the therapeutic values of cell transplantation and gene delivery. These remarkable developments from many disciplines have generated a new level of optimism in the search for a cure for CNS injury and in particular spinal cord injury. In this review, the authors summarize recent progress in these strategies and some of the challenges that remain in elucidating the most efficacious protocols for rescuing injured neurons, encouraging regeneration of their axons, and promoting recovery of function.

Entities:  

Mesh:

Year:  2001        PMID: 11486342     DOI: 10.1177/107385840100700107

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  7 in total

1.  Aspiration of a cervical spinal contusion injury in preparation for delayed peripheral nerve grafting does not impair forelimb behavior or axon regeneration.

Authors:  Harra R Sandrow; Jed S Shumsky; Arthi Amin; John D Houle
Journal:  Exp Neurol       Date:  2007-12-15       Impact factor: 5.330

Review 2.  Schwann cell transplantation and descending propriospinal regeneration after spinal cord injury.

Authors:  Ling-Xiao Deng; Chandler Walker; Xiao-Ming Xu
Journal:  Brain Res       Date:  2014-09-26       Impact factor: 3.252

3.  Treatment of spinal cord injury with co-grafts of genetically modified Schwann cells and fetal spinal cord cell suspension in the rat.

Authors:  Shi-Qing Feng; Xiao-Hong Kong; Shi-Fu Guo; Pei Wang; Li Li; Jin-Hua Zhong; Xin-Fu Zhou
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 4.  Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.

Authors:  Yirui Feng; Yu Li; Ping-Ping Shen; Bin Wang
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 5.739

5.  Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.

Authors:  Courtney Paul; Amer F Samdani; Randal R Betz; Itzhak Fischer; Birgit Neuhuber
Journal:  Spine (Phila Pa 1976)       Date:  2009-02-15       Impact factor: 3.468

6.  Blockade of peroxynitrite-induced neural stem cell death in the acutely injured spinal cord by drug-releasing polymer.

Authors:  Dou Yu; William L Neeley; Christopher D Pritchard; Jonathan R Slotkin; Eric J Woodard; Robert Langer; Yang D Teng
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277

7.  Hypoxic preconditioned bone mesenchymal stem cells ameliorate spinal cord injury in rats via improved survival and migration.

Authors:  Weiheng Wang; Xiaodong Huang; Wenbo Lin; Yuanyuan Qiu; Yunfei He; Jiangming Yu; Yanhai Xi; Xiaojian Ye
Journal:  Int J Mol Med       Date:  2018-08-07       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.